The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone

The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone

<b>Background:</b> Either sodium-glucose cotransporter-2 (SGLT-2) inhibitors or pioglitazone (Pio) has doubtful issues of bladder cancer, especially for the combination therapy with these two drugs. Our study aimed to investigate the risk of bladder cancer under combination therapy of SG...

Full description

Bibliographic Details
Main Authors: Yan-Rong Li, Chi-Hung Liu, Wei-Chiao Sun, Pei-Yi Fan, Feng-Hsuan Liu, Tien-Hsing Chen, Victor Chien-Chia Wu, Chihung Lin, Ching-Chung Hsiao
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Journal of Personalized Medicine
Subjects:
type 2 diabetes mellitus
bladder cancer
sodium glucose cotransporter-2 (SGLT-2) inhibitors
pioglitazone
mortality
Online Access:https://www.mdpi.com/2075-4426/11/9/828

Internet

https://www.mdpi.com/2075-4426/11/9/828

Similar Items